Schambach Axel, Galla Melanie, Modlich Ute, Will Elke, Chandra Saurabh, Reeves Lilith, Colbert Melissa, Williams David A, von Kalle Christof, Baum Christopher
Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Germany.
Exp Hematol. 2006 May;34(5):588-92. doi: 10.1016/j.exphem.2006.02.005.
Lentiviral vectors are increasingly used for preclinical models of gene therapy and other forms of experimental transgenesis. Due to the broad tropism and the ability for concentration by ultracentrifugation, most lentiviral vector preparations are produced using the vesicular stomatitis virus glycoprotein (VSV-g) protein as envelope. Recently, Hanawa and colleagues have demonstrated that the ecotropic envelope protein of murine leukemia viruses allows efficient pseudotyping of HIV-1-derived vector particles. However, this method has found little acceptance, despite potential advantages.
We produced lentiviral vectors pseudotyped with murine ecotropic envelope using a four-plasmid transient transfection system and evaluated their performance in murine fibroblasts and hematopoietic cells.
Titers of lentiviral "ecotropic" supernatants were only slightly lower than those produced with VSV-g, could be concentrated by overnight centrifugation (13,000g), and efficiently transduced murine fibroblasts and hematopoietic cells but not human cells. Our Institutional Biosafety Committee agreed on the production and use of replication-defective lentiviral vectors pseudotyped with murine ecotropic envelope under biosafety level 1 (BL1) conditions with additional BL2 practices. We also obtained useful guidelines for the work with human infectious lentiviral vectors.
For the researcher, "ecotropic" lentiviral vectors significantly improve the convenience of daily work, compared to the conditions required for lentiviral pseudotypes that are capable of infecting human cells. High efficiency and superior biosafety in combination with convenient handling will certainly boost the potential applicability of this important vector system.
慢病毒载体越来越多地用于基因治疗的临床前模型和其他形式的实验性转基因。由于其广泛的嗜性以及通过超速离心进行浓缩的能力,大多数慢病毒载体制剂是使用水泡性口炎病毒糖蛋白(VSV-g)作为包膜产生的。最近,花轮及其同事证明,鼠白血病病毒的嗜亲性包膜蛋白可使HIV-1衍生的载体颗粒高效假型化。然而,尽管有潜在优势,但该方法却很少被采用。
我们使用四质粒瞬时转染系统制备了用鼠嗜亲性包膜假型化的慢病毒载体,并评估了它们在鼠成纤维细胞和造血细胞中的性能。
慢病毒“嗜亲性”上清液的滴度仅略低于用VSV-g产生的滴度,可通过过夜离心(13,000g)进行浓缩,并且能高效转导鼠成纤维细胞和造血细胞,但不能转导人类细胞。我们的机构生物安全委员会同意在生物安全1级(BL1)条件下并采用额外的BL2措施来生产和使用用鼠嗜亲性包膜假型化的复制缺陷型慢病毒载体。我们还获得了有关处理人类感染性慢病毒载体工作的有用指南。
对于研究人员而言,与能够感染人类细胞的慢病毒假型所需的条件相比,“嗜亲性”慢病毒载体显著提高了日常工作的便利性。高效、卓越的生物安全性以及便捷的操作肯定会提升这一重要载体系统的潜在适用性。